Revvity (RVTY)
Market Price (12/28/2025): $96.735 | Market Cap: $11.2 BilSector: Health Care | Industry: Health Care Equipment
Revvity (RVTY)
Market Price (12/28/2025): $96.735Market Cap: $11.2 BilSector: Health CareIndustry: Health Care Equipment
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 20%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 18% | Weak multi-year price returns2Y Excs Rtn is -54%, 3Y Excs Rtn is -111% | Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 31x, P/EPrice/Earnings or Price/(Net Income) is 47x |
| Low stock price volatilityVol 12M is 38% | Weak revenue growthRev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -7.2% | |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Advanced Diagnostics, Personalized Diagnostics, Show more. |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 20%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 18% |
| Low stock price volatilityVol 12M is 38% |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Advanced Diagnostics, Personalized Diagnostics, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -54%, 3Y Excs Rtn is -111% |
| Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 31x, P/EPrice/Earnings or Price/(Net Income) is 47x |
| Weak revenue growthRev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -7.2% |
Why The Stock Moved
Qualitative Assessment
AI Analysis | Feedback
<b>1. Disappointing Q3 2025 Financial Results and Lowered Outlook.</b> Revvity announced its third-quarter 2025 financial results on October 27, 2025, reporting revenue of $699 million, representing 2% reported growth and 1% organic growth. However, the company also lowered its full-year outlook, which was perceived as disappointing by investors.
<br><br>
<b>2. Issuance of a Sell Signal and Negative Analyst Sentiment.</b> A significant factor contributing to the stock's movement was the issuance of a sell signal from a pivot top point on Tuesday, November 25, 2025, after which the stock experienced an 8.84% decline. This was further influenced by negative market sentiment, as indicated by articles in December 2025 highlighting risks associated with RVTY.
<br><br>
<b>3. Strategic Acquisition of ACD/Labs.</b> On November 10, 2025, Revvity announced its intention to acquire ACD/Labs. This acquisition aimed to expand Revvity's Signals Software Capabilities and deepen its presence in research informatics. While strategically important, market reactions to acquisitions can vary, potentially leading to short-term stock price adjustments.
<br><br>
<b>4. Underperformance Relative to Market and Industry.</b> Over the past year, Revvity's stock underperformed both the broader U.S. market, which returned 15.8%, and the U.S. Life Sciences industry, which returned 3%. This ongoing underperformance contributed to a negative investment sentiment during the period.
<br><br>
<b>5. Pressures from Regulatory Shifts and Market Declines.</b> Revvity faced challenges from regulatory shifts and market-specific declines, which were identified as threats to its revenue growth and earnings recovery. These broader industry pressures impacted the company's financial stability and margin expansion, despite its efforts in innovation and high-growth segments.
Show moreStock Movement Drivers
Fundamental Drivers
The 15.2% change in RVTY stock from 9/27/2025 to 12/27/2025 was primarily driven by a 35.9% change in the company's P/E Multiple.| 9272025 | 12272025 | Change | |
|---|---|---|---|
| Stock Price ($) | 84.00 | 96.75 | 15.18% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 2798.47 | 2813.37 | 0.53% |
| Net Income Margin (%) | 10.19% | 8.44% | -17.17% |
| P/E Multiple | 34.61 | 47.02 | 35.85% |
| Shares Outstanding (Mil) | 117.51 | 115.41 | 1.79% |
| Cumulative Contribution | 15.15% |
Market Drivers
9/27/2025 to 12/27/2025| Return | Correlation | |
|---|---|---|
| RVTY | 15.2% | |
| Market (SPY) | 4.3% | 50.7% |
| Sector (XLV) | 15.2% | 61.7% |
Fundamental Drivers
The -0.9% change in RVTY stock from 6/28/2025 to 12/27/2025 was primarily driven by a -18.4% change in the company's Net Income Margin (%).| 6282025 | 12272025 | Change | |
|---|---|---|---|
| Stock Price ($) | 97.68 | 96.75 | -0.95% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 2769.87 | 2813.37 | 1.57% |
| Net Income Margin (%) | 10.35% | 8.44% | -18.42% |
| P/E Multiple | 40.94 | 47.02 | 14.84% |
| Shares Outstanding (Mil) | 120.14 | 115.41 | 3.93% |
| Cumulative Contribution | -1.10% |
Market Drivers
6/28/2025 to 12/27/2025| Return | Correlation | |
|---|---|---|
| RVTY | -0.9% | |
| Market (SPY) | 12.6% | 39.0% |
| Sector (XLV) | 17.0% | 61.5% |
Fundamental Drivers
The -13.4% change in RVTY stock from 12/27/2024 to 12/27/2025 was primarily driven by a -12.8% change in the company's P/E Multiple.| 12272024 | 12272025 | Change | |
|---|---|---|---|
| Stock Price ($) | 111.68 | 96.75 | -13.37% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 2721.55 | 2813.37 | 3.37% |
| Net Income Margin (%) | 9.34% | 8.44% | -9.66% |
| P/E Multiple | 53.93 | 47.02 | -12.82% |
| Shares Outstanding (Mil) | 122.81 | 115.41 | 6.02% |
| Cumulative Contribution | -13.68% |
Market Drivers
12/27/2024 to 12/27/2025| Return | Correlation | |
|---|---|---|
| RVTY | -13.4% | |
| Market (SPY) | 17.0% | 56.8% |
| Sector (XLV) | 13.8% | 67.6% |
Fundamental Drivers
The -29.4% change in RVTY stock from 12/28/2022 to 12/27/2025 was primarily driven by a -51.9% change in the company's Net Income Margin (%).| 12282022 | 12272025 | Change | |
|---|---|---|---|
| Stock Price ($) | 137.02 | 96.75 | -29.39% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 3598.52 | 2813.37 | -21.82% |
| Net Income Margin (%) | 17.55% | 8.44% | -51.91% |
| P/E Multiple | 27.36 | 47.02 | 71.82% |
| Shares Outstanding (Mil) | 126.16 | 115.41 | 8.52% |
| Cumulative Contribution | -29.90% |
Market Drivers
12/28/2023 to 12/27/2025| Return | Correlation | |
|---|---|---|
| RVTY | -12.2% | |
| Market (SPY) | 48.0% | 51.4% |
| Sector (XLV) | 17.9% | 61.0% |
Price Returns Compared
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| RVTY Return | 48% | 40% | -30% | -22% | 2% | -13% | 1% |
| Peers Return | 16% | 38% | -12% | 21% | 26% | 16% | 150% |
| S&P 500 Return | 16% | 27% | -19% | 24% | 23% | 18% | 114% |
Monthly Win Rates [3] | |||||||
| RVTY Win Rate | 58% | 83% | 50% | 42% | 33% | 42% | |
| Peers Win Rate | 52% | 65% | 42% | 68% | 57% | 52% | |
| S&P 500 Win Rate | 58% | 75% | 42% | 67% | 75% | 73% | |
Max Drawdowns [4] | |||||||
| RVTY Max Drawdown | -31% | -16% | -42% | -41% | -9% | -26% | |
| Peers Max Drawdown | -34% | -5% | -26% | -7% | -9% | -23% | |
| S&P 500 Max Drawdown | -31% | -1% | -25% | -1% | -2% | -15% | |
[1] Cumulative total returns since the beginning of 2020
[2] Peers: HPQ, HPE, IBM, CSCO, AAPL.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 12/26/2025 (YTD)
How Low Can It Go
| Event | RVTY | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -59.2% | -25.4% |
| % Gain to Breakeven | 145.0% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -34.4% | -33.9% |
| % Gain to Breakeven | 52.5% | 51.3% |
| Time to Breakeven | 77 days | 148 days |
| 2018 Correction | ||
| % Loss | -26.1% | -19.8% |
| % Gain to Breakeven | 35.3% | 24.7% |
| Time to Breakeven | 87 days | 120 days |
| 2008 Global Financial Crisis | ||
| % Loss | -63.0% | -56.8% |
| % Gain to Breakeven | 169.9% | 131.3% |
| Time to Breakeven | 1,285 days | 1,480 days |
Compare to HPQ, HPE, IBM, CSCO, AAPL
In The Past
Revvity's stock fell -59.2% during the 2022 Inflation Shock from a high on 12/31/2021. A -59.2% loss requires a 145.0% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth over time.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
AI Analysis | Feedback
Revvity is like Thermo Fisher Scientific for specialized life science and diagnostic solutions.
Revvity is similar to Agilent Technologies for advanced scientific instruments and diagnostic tools.
AI Analysis | Feedback
- Life Sciences Research Instruments & Reagents: Provides specialized laboratory instruments, reagents, and consumables used in drug discovery, genomics, cell biology, and other advanced research applications.
- Diagnostic Solutions: Offers a range of products and services for disease detection, including newborn screening, prenatal testing, and infectious disease diagnostics.
- Informatics Software & Services: Delivers software platforms and data analytics solutions to manage, analyze, and interpret complex biological and clinical data.
AI Analysis | Feedback
Revvity (symbol: RVTY) primarily sells its products and services to other companies and institutions, making it a business-to-business (B2B) company.
Revvity does not publicly disclose the names of specific major customers in its financial reports or other public statements. This is common for companies like Revvity, which serve a broad and diverse customer base across multiple segments globally. Instead of individual company names, their customer base can be described by the following major categories of organizations they serve:
- Pharmaceutical and Biotechnology Companies: These companies are major customers, utilizing Revvity's life science research tools, reagents, software, and services for drug discovery, development, and manufacturing processes. This category includes a vast number of public and private companies globally.
- Academic and Government Research Institutions: Universities, research hospitals, and government laboratories (such as those funded by organizations like the National Institutes of Health (NIH)) are significant customers, relying on Revvity's solutions for fundamental and applied scientific research. These are typically not public companies.
- Clinical Diagnostic Laboratories and Healthcare Providers: Revvity's diagnostic products, used for areas like reproductive health, infectious disease testing, and applied genomics, are sold to clinical laboratories, hospitals, and other healthcare providers. This category includes both large public laboratory networks and smaller private entities.
- Food, Environmental, and Industrial Markets: This segment encompasses companies and laboratories in various industries that require analytical solutions for quality control, safety testing, and compliance. Examples include food and beverage manufacturers, environmental testing firms, and industrial research and quality control labs. This category includes a mix of public and private companies.
AI Analysis | Feedback
nullAI Analysis | Feedback
Prahlad Singh President and Chief Executive Officer
Prahlad Singh was appointed President and Chief Executive Officer of Revvity (formerly PerkinElmer) in December 2019, having joined the company in May 2014 as President of the Diagnostics business. He led the company through a significant transformation, including navigating the COVID-19 pandemic and overseeing its portfolio evolution. Notably, he was at the helm when the company completed the divestiture of its Applied, Food and Enterprise Services businesses to New Mountain Capital, a transaction that resulted in the creation of Revvity. Prior to Revvity, he served as General Manager of GE Healthcare's Women's Health business from 2012 to 2014. His career also includes senior executive roles in strategy, business development, and mergers and acquisitions at both GE Healthcare and Philips Healthcare. Earlier, from 1995 to 2007, he held leadership positions at DuPont Pharmaceuticals and Bristol-Myers Squibb Medical Imaging. Dr. Singh holds a PhD in chemistry from the University of Missouri-Columbia and an MBA from Northeastern University.
Max Krakowiak Senior Vice President and Chief Financial Officer
Max Krakowiak serves as the Senior Vice President and Chief Financial Officer at Revvity, a role he assumed in 2023, following his appointment as CFO of PerkinElmer in August 2022. He has been a key member of Revvity's finance leadership team since 2018. Before his current position, he was the Vice President of Corporate Finance, overseeing financial planning and analysis, as well as commercial and business development finance. Krakowiak spent seven years at GE, most recently as a member of the executive leadership team in the company's corporate audit staff, where he oversaw teams responsible for corporate strategy, external investigations, and investor relations across global operating segments. He is also an alumnus of the GE Financial Management leadership program. Additionally, he had a brief career as a minor league baseball player for the Seattle Mariners organization. Krakowiak earned a bachelor's degree in finance from Fordham University.
Joel Goldberg Senior Vice President, Administration, General Counsel and Secretary
Joel Goldberg holds the position of Senior Vice President, Administration, General Counsel and Secretary at Revvity. In this role, he provides expert insights and strategic guidance on a range of legal, regulatory, and policy matters affecting the company. He leads dedicated teams focused on providing collaborative support and guidance across various corporate issues and business functions.
Magali Four Senior Vice President, Chief People and Culture Officer
Magali Four is the Senior Vice President, Chief People and Culture Officer at Revvity. (Detailed background information was not available in the provided search results.)
Tajinder Vohra Senior Vice President of Global Operations
Tajinder Vohra serves as the Senior Vice President of Global Operations at Revvity, a role he has held since 2015. He is responsible for overseeing the company's manufacturing, supply chain, customer care, and distribution functions. With nearly 30 years of experience in operations management, he leads a global team that collaborates closely with R&D and Product Management to facilitate the launch and manufacturing of products across Revvity's Life Sciences and Diagnostics businesses.
AI Analysis | Feedback
nullAI Analysis | Feedback
The rapid acceleration and adoption of artificial intelligence (AI), machine learning (ML), and advanced computational biology platforms represent an emerging threat. These technologies are increasingly capable of dramatically accelerating drug discovery, target identification, and diagnostic insights with potentially reduced reliance on traditional, iterative wet lab experimentation that underpins demand for Revvity's specialized laboratory instruments and reagents. As AI-driven solutions become more predictive and efficient, they could lead to a fundamental shift in research and diagnostic paradigms, potentially commoditizing certain physical lab tools or reducing the overall volume of specialized reagent consumption by making discovery more computationally intensive. Additionally, the rise of cloud-native, integrated data platforms and open-source lab automation solutions offers alternatives to Revvity's proprietary ecosystems, enabling labs to build more flexible, vendor-agnostic infrastructures that could diminish the value proposition of tightly bundled, proprietary offerings.
AI Analysis | Feedback
Revvity (symbol: RVTY) operates in significant global markets for its life sciences and diagnostics products and services. The company's estimated total addressable market (TAM) globally exceeds $60 billion.
More specifically, Revvity is a key player in several large and growing segments:
- Genomics Market: The global genomics market was valued at approximately US$42.6 billion in 2024 and is projected to reach US$66.8 billion by 2029.
- Proteomics Market: The global proteomics market was valued at approximately US$33.64 billion in 2024 and is projected to reach US$60.36 billion by 2029. Other estimates place the global proteomics market size at $32.8 billion in 2023, with a projection to reach $161.9 billion by 2035, or $24.2 billion in 2023, projected to reach $73.9 billion by 2032.
- Molecular Cytogenetics Market: The global molecular cytogenetics market size is estimated at USD 2.86 billion in 2025 and is projected to grow to approximately USD 7.82 billion by 2034. For the U.S. specifically, this market is valued at USD 962.90 million in 2025 and is projected to reach around USD 2,650.16 million by 2034.
AI Analysis | Feedback
Expected Drivers of Future Revenue Growth for Revvity (RVTY)
Revvity (NYSE: RVTY) is anticipated to drive future revenue growth over the next 2-3 years through several key areas, as indicated by recent earnings calls and analyst commentary:
- Continued Strength in the Diagnostics Segment: The Diagnostics business is consistently highlighted as a strong performer, with specific mentions of robust growth in reproductive health and immunodiagnostics. This segment "continues to do very well" and led growth with a 3% revenue increase in Q3 2025. The specialty diagnostic businesses have "strong and durable underlying market growth drivers that are more immune to changes in the macroeconomic environment".
- Expansion of the Software Business, particularly the Signals Software Franchise: Revvity's software business has demonstrated strong performance. The "Signals software franchise" exhibited approximately 30% organic growth in Q2 2025, contributing significantly to the Life Sciences segment's organic growth.
- Launch of New Products, including AI-driven Solutions, and Strategic Partnerships: The company's President and CEO, Prahlad Singh, emphasized that "key new product launches and strategic partnership initiatives" are coming to fruition and positioning the company for greater success in 2026 and beyond. AI-driven product launches have also been specifically highlighted as growth drivers.
- Recovery in Broader Industry Demand and Customer Activity: While the instrumentation business has faced challenges, management has noted a "path to recovery" and "improving signs of customer activity". The company is "positioned well to have a strong finish to the year with positive momentum as we head into 2026," contingent on sustained improvements in broader industry demand trends.
- Growth in the Reagents Business within Life Sciences: Despite declines in the instrumentation aspect of the Life Sciences segment, the reagents business has shown "solid growth". This indicates a resilient component within the Life Sciences portfolio that is expected to contribute to overall revenue.
AI Analysis | Feedback
Share Repurchases
- In October 2024, Revvity's Board of Directors authorized a new two-year $1 billion share repurchase program, which superseded a prior program announced in May 2023.
- Under the buyback program announced in November 2024, Revvity had repurchased shares totaling $627.06 million as of August 5, 2025.
- During the three months ended September 29, 2024, the company repurchased $153.4 million in common stock.
Share Issuance
- Revvity issued 14,339 shares of common stock in fiscal year 2024 under its Employee Stock Purchase Plan at a weighted-average price of $99.62 per share.
- In fiscal year 2023, 28,899 shares were issued at a weighted-average price of $108.37 per share through the Employee Stock Purchase Plan.
- For fiscal year 2022, 30,818 shares were issued under the Employee Stock Purchase Plan at a weighted-average price of $134.05 per share.
Outbound Investments
- In 2021, Revvity (operating as PerkinElmer at the time) acquired BioLegend, a global provider of life science antibodies and reagents, for $5.7 billion (net of cash acquired).
- Also in 2021, the company acquired Nexcelom and Oxford Immunotec for an aggregate of $1.2 billion, aiming to enhance its Life Sciences and Diagnostics segments.
Capital Expenditures
- Revvity reported capital expenditures of $86.6 million for fiscal year 2024, an increase from $81.4 million in fiscal year 2023.
- The company anticipates an increase in capital expenditures for fiscal year 2025, driven by a strategic focus on enhancing digital capabilities, product innovations, and realigning production infrastructure.
- Capital expenditure remains a pressured area, with a focus on regional manufacturing and investments in differentiated specialty diagnostics.
Latest Trefis Analyses
| Title | Topic | |
|---|---|---|
| DASHBOARDS | ||
| Revvity Earnings Notes | ||
| Revvity Earnings Notes | ||
| Revvity Earnings Notes | ||
| Better Value & Growth: MDT, RMD Top Revvity Stock | Actionable | |
| Is Revvity Stock Built to Withstand More Downside? | Return | |
| Revvity vs Microsoft: Which Is A Better Investment? | Counter-Intuitive Comparisons | |
| Revvity vs Eli Lilly: Which Is A Better Investment? | Counter-Intuitive Comparisons | |
| Revvity vs Becton Dickinson: Which Is A Better Investment? | Counter-Intuitive Comparisons | |
| How Does Revvity Stock Stack Up Against Its Peers? | Peer Comparison | |
| Better Bet Than RVTY Stock: Pay Less Than Revvity To Get More From MRK, BMRNÂ |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to RVTY. For more, see Trefis Trade Ideas.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 11142025 | CRL | Charles River Laboratories International | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 21.4% | 21.4% | -3.7% |
| 11142025 | GDRX | GoodRx | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | -7.4% | -7.4% | -11.8% |
| 11142025 | ASTH | Astrana Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 18.0% | 18.0% | -5.5% |
| 11142025 | SGRY | Surgery Partners | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 3.9% | 3.9% | -1.4% |
| 11072025 | TFX | Teleflex | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 12.2% | 12.2% | -5.1% |
| 09122025 | RVTY | Revvity | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 16.8% | 16.8% | 0.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons for Revvity
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 87.45 |
| Mkt Cap | 158.8 |
| Rev LTM | 56,496 |
| Op Inc LTM | 7,584 |
| FCF LTM | 7,327 |
| FCF 3Y Avg | 7,366 |
| CFO LTM | 8,590 |
| CFO 3Y Avg | 8,697 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 5.2% |
| Rev Chg 3Y Avg | 2.2% |
| Rev Chg Q | 8.3% |
| QoQ Delta Rev Chg LTM | 2.0% |
| Op Mgn LTM | 15.3% |
| Op Mgn 3Y Avg | 14.3% |
| QoQ Delta Op Mgn LTM | -0.1% |
| CFO/Rev LTM | 20.5% |
| CFO/Rev 3Y Avg | 18.3% |
| FCF/Rev LTM | 17.9% |
| FCF/Rev 3Y Avg | 15.4% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 158.8 |
| P/S | 4.2 |
| P/EBIT | 23.8 |
| P/E | 38.5 |
| P/CFO | 20.3 |
| Total Yield | 3.9% |
| Dividend Yield | 2.1% |
| FCF Yield 3Y Avg | 5.7% |
| D/E | 0.3 |
| Net D/E | 0.2 |
Segment Financials
Revenue by Segment| $ Mil | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Diagnostics | 1,458 | 2,020 | 2,933 | 2,067 | 1,138 |
| Life Sciences | 1,292 | 1,293 | 898 | 1,716 | 1,746 |
| Revenue purchase accounting adjustments | -1 | -3 | |||
| Total | 2,751 | 3,312 | 3,828 | 3,783 | 2,884 |
| $ Mil | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Life Sciences | 489 | 503 | 282 | 183 | 238 |
| Diagnostics | 320 | 782 | 1,433 | 874 | 189 |
| Asset impairment | 0 | 0 | |||
| Significant litigation matters and settlements | -0 | 1 | |||
| Significant environmental matters | -2 | 0 | |||
| Purchase accounting adjustments | -5 | -46 | -41 | ||
| Restructuring and other, net | -27 | -14 | -18 | ||
| Corporate expenses | -40 | -73 | -77 | -79 | -66 |
| Acquisition and divestiture-related costs | -69 | -40 | -63 | ||
| Amortization of intangible assets | -365 | -371 | -257 | ||
| Total | 301 | 743 | 1,258 | 979 | 362 |
Price Behavior
| Market Price | $96.75 | |
| Market Cap ($ Bil) | 11.2 | |
| First Trading Date | 12/29/2006 | |
| Distance from 52W High | -23.6% | |
| 50 Days | 200 Days | |
| DMA Price | $96.91 | $94.51 |
| DMA Trend | down | up |
| Distance from DMA | -0.2% | 2.4% |
| 3M | 1YR | |
| Volatility | 33.4% | 38.3% |
| Downside Capture | 123.25 | 138.89 |
| Upside Capture | 166.61 | 103.28 |
| Correlation (SPY) | 51.0% | 56.7% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 1.16 | 1.26 | 1.33 | 1.34 | 1.11 | 1.00 |
| Up Beta | 1.64 | 1.47 | 1.99 | 1.63 | 1.11 | 0.94 |
| Down Beta | -0.35 | 1.35 | 1.12 | 0.73 | 1.02 | 0.97 |
| Up Capture | 261% | 191% | 158% | 152% | 102% | 67% |
| Bmk +ve Days | 12 | 25 | 38 | 73 | 141 | 426 |
| Stock +ve Days | 10 | 21 | 31 | 65 | 118 | 367 |
| Down Capture | 56% | 73% | 103% | 149% | 115% | 105% |
| Bmk -ve Days | 7 | 16 | 24 | 52 | 107 | 323 |
| Stock -ve Days | 9 | 20 | 31 | 60 | 130 | 382 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Comparison of RVTY With Other Asset Classes (Last 1Y) | |||||||
|---|---|---|---|---|---|---|---|
| RVTY | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | -13.8% | 15.1% | 17.8% | 72.1% | 8.6% | 4.4% | -8.2% |
| Annualized Volatility | 38.0% | 17.2% | 19.4% | 19.3% | 15.2% | 17.0% | 35.0% |
| Sharpe Ratio | -0.31 | 0.65 | 0.72 | 2.70 | 0.34 | 0.09 | -0.08 |
| Correlation With Other Assets | 67.5% | 56.6% | -1.7% | 13.5% | 55.9% | 21.9% | |
ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Comparison of RVTY With Other Asset Classes (Last 5Y) | |||||||
|---|---|---|---|---|---|---|---|
| RVTY | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | -7.4% | 8.4% | 14.7% | 18.7% | 11.5% | 4.6% | 30.8% |
| Annualized Volatility | 33.1% | 14.5% | 17.1% | 15.5% | 18.7% | 18.9% | 48.6% |
| Sharpe Ratio | -0.17 | 0.40 | 0.70 | 0.97 | 0.50 | 0.16 | 0.57 |
| Correlation With Other Assets | 58.2% | 53.0% | 12.5% | 8.2% | 49.5% | 22.1% | |
ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Comparison of RVTY With Other Asset Classes (Last 10Y) | |||||||
|---|---|---|---|---|---|---|---|
| RVTY | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | 6.7% | 9.9% | 14.8% | 15.3% | 7.0% | 5.3% | 69.2% |
| Annualized Volatility | 30.1% | 16.6% | 18.0% | 14.7% | 17.6% | 20.8% | 55.8% |
| Sharpe Ratio | 0.28 | 0.49 | 0.71 | 0.86 | 0.32 | 0.22 | 0.90 |
| Correlation With Other Assets | 61.0% | 58.5% | 7.5% | 16.3% | 45.1% | 14.8% | |
ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 10/27/2025 | -1.7% | -5.4% | 1.7% |
| 7/28/2025 | -8.3% | -14.9% | -11.1% |
| 4/28/2025 | 0.8% | -0.3% | -2.2% |
| 1/31/2025 | -0.6% | -6.1% | -13.0% |
| 11/4/2024 | 3.1% | 1.2% | -5.0% |
| 7/29/2024 | 9.1% | 7.1% | 5.2% |
| 4/29/2024 | 3.5% | -0.9% | 10.2% |
| 1/9/2024 | 2.1% | -0.8% | -5.5% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 11 | 7 | 11 |
| # Negative | 13 | 17 | 13 |
| Median Positive | 3.5% | 6.9% | 5.2% |
| Median Negative | -1.7% | -5.1% | -8.8% |
| Max Positive | 9.1% | 10.9% | 19.1% |
| Max Negative | -16.1% | -14.9% | -13.0% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 9302025 | 11042025 | 10-Q 9/28/2025 |
| 6302025 | 8052025 | 10-Q 6/29/2025 |
| 3312025 | 5062025 | 10-Q 3/30/2025 |
| 12312024 | 2252025 | 10-K 12/29/2024 |
| 9302024 | 11062024 | 10-Q 9/29/2024 |
| 6302024 | 8062024 | 10-Q 6/30/2024 |
| 3312024 | 5072024 | 10-Q 3/31/2024 |
| 12312023 | 2272024 | 10-K 12/31/2023 |
| 9302023 | 11072023 | 10-Q 10/1/2023 |
| 6302023 | 8092023 | 10-Q 7/2/2023 |
| 3312023 | 5122023 | 10-Q 4/2/2023 |
| 12312022 | 3012023 | 10-K 1/1/2023 |
| 9302022 | 11142022 | 10-Q 10/2/2022 |
| 6302022 | 8092022 | 10-Q 7/3/2022 |
| 3312022 | 5102022 | 10-Q 4/3/2022 |
| 12312021 | 3032022 | 10-K 1/2/2022 |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.